Accelerometer use in a physical activity intervention trial
Accelerometer use in a physical activity intervention trial
复制标题
DOI：
10.1016/j.cct.2010.08.004
复制
发表时间：
2010-11-01
影响因子：
2.2
通讯作者：
Marcus, Bess H.
中科院分区：
文献类型：
--
作者：
Napolitano, Melissa A.;Borradaile, Kelley E.;Marcus, Bess H.
本文描述了在体育活动（PA）干预试验中使用加速度计的最佳实践建议的应用，以及测量PA的不同方法的一致性。参与PA试验的239名健康、久坐的成年人（平均年龄47.5岁，82%为女性）中，有一个子样本（n = 63, 26%）在所有3个评估时间点都佩戴了ActiGraph监测仪。将ActiGraph数据与自我报告(即…PA每周召回和每月日志)和适应度变量。中度强度活动的PA回忆和ActiGraph之间的相关性为0.16-0.48，剧烈强度活动的PA回忆和ActiGraph之间的相关性为0.28-0.42。ActiGraph和fitness[估计的VO2(ml/kg/min)]的相关性为0.15-0.45。ActiGraph和每周自我报告在所有时间点上均显著相关（相关性范围为0.23 ~ 0.44）。在检测干预效果方面，干预组在6个月时在ActiGraph上记录的至少中等强度PA的分钟数比对照组多（min = 46.47, 95% Cl = -14.36-78.58），但在12个月时则没有。该研究的局限性包括样本量小，仅进行了3天的ActiGraph监测。为了在临床试验中使用加速度计获得最佳结果，作者推荐以下最佳实践建议：监测使用的详细协议，监测校准和数据质量验证，以及使用经过验证的方程进行分析。ActiGraph与其他评估工具有一定的一致性，并且对随时间的变化很敏感。然而，直到有更多的信息证实加速度计在临床试验中的应用。适当管理的PA自我报告措施应继续作为评估的一部分。(C) 2010爱思唯尔公司版权所有。
This paper describes the application of best practice recommendations for using accelerometers in a physical activity (PA) intervention trial, and the concordance of different methods for measuring PA. A subsample (n = 63; 26%) of the 239 healthy, sedentary adults participating in a PA trial (mean age = 47.5; 82% women) wore the ActiGraph monitor at all 3 assessment time points. ActiGraph data were compared with self-report (i.e.. PA weekly recall and monthly log) and fitness variables. Correlations between the PA recall and ActiGraph for moderate intensity activity ranged from 0.16-0.48 and from 0.28-0.42 for vigorous intensity activity. ActiGraph and fitness [estimated VO2(ml/kg/min)] had correlations of 0.15-0.45. The ActiGraph and weekly self-report were significantly correlated at all time points (correlations ranged from 0.23 to 0.44). In terms of detecting intervention effects, intervention groups recorded more minutes of at least moderate-intensity PA on the ActiGraph than the control group at 6 months (min = 46.47, 95% Cl = -14.36-78.58), but not at 12 months. Limitations of the study include a small sample size and only 3 days of ActiGraph monitoring. To obtain optimal results with accelerometers in clinical trials, the authors recommend following best practice recommendations: detailed protocols for monitor use, calibration of monitors and validation of data quality, and use of validated equations for analysis. The ActiGraph has modest concordance with other assessment tools and is sensitive to change over time. However, until more information validating the use of accelerometry in clinical trials becomes available. properly administered self-report measures of PA should remain part of the assessment battery. (C) 2010 Elsevier Inc. All rights reserved.